▲ bullish
Impact
PhasePhase 2
Time to marketAt least 2-3 years away, assuming positive Phase 2 data in November 2026, an end-of-Phase 2 meeting with regulators in 1H 2027, a subsequent Phase 3 program, and eventual NDA filing.
PGN-EDODM1 Updated Sep 1
What to watch
Watch for the 10 mg/kg data readout from the FREEDOM2-DM1 study expected in November 2026, positive splicing-correction data could drive a significant re-rate given the stock's ~$3.11 price vs. the $10.19 mean analyst target. However, the unresolved FDA partial clinical hold and the active $100M ATM facility are overhangs that could cap upside or accelerate dilution.
Bull case
- DSMB recommended advancing PGN-EDODM1 to the highest 12.5 mg/kg dose cohort with no protocol changes and approved OLE dose escalation to 10 mg/kg, confirming a favorable safety profile through multiple dose levels.
- Analyst consensus is overwhelmingly bullish: 12 Buy/Strong Buy ratings vs. just 1 Hold and 1 Sell, with a mean price target of $10.19 (237% implied upside from the current ~$3.11 price).
- RA Capital Management holds a $36.1M position (20M+ shares) as the largest institutional holder, signaling deep-pocketed specialist conviction.
Bear case
- FDA partial clinical hold on the FREEDOM2 study remains unresolved since March 2026, creating regulatory uncertainty that could delay or derail the program.
- A $400M universal shelf registration (including a $100M ATM facility) became effective in May 2026, creating significant dilution overhang for existing shareholders.
- Several institutional investors (Morgan Stanley, Barclays, BNP Paribas, Susquehanna) executed near-exit trims in Q2 2026, signaling mixed conviction among sophisticated holders.